B-CELL MALIGNANCIES
Clinical trials for B-CELL MALIGNANCIES explained in plain language.
Never miss a new study
Get alerted when new B-CELL MALIGNANCIES trials appear
Sign up with your email to follow new studies for B-CELL MALIGNANCIES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo targets tough blood cancers in early trial
Disease control OngoingThis early-phase study tests a new drug, INCB040093, alone or with another drug (itacitinib) in 121 adults with B-cell blood cancers that have come back or not responded to prior treatment. The main goal is to find safe doses and check for side effects. Researchers will also look…
Matched conditions: B-CELL MALIGNANCIES
Phase: PHASE1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated May 01, 2026 16:01 UTC
-
Lifeline for B-Cell cancer patients: continued access to experimental drug
Disease control OngoingThis study offers continued access to the drug parsaclisib (alone or with other medicines) for people with B-cell cancers who were already benefiting from it in earlier Incyte studies. About 112 participants will receive the treatment and be monitored for side effects. The goal i…
Matched conditions: B-CELL MALIGNANCIES
Phase: PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated May 01, 2026 15:59 UTC
-
Cancer drug Zanubrutinib's Long-Term safety tracked in 955-Patient extension study
Disease control OngoingThis study looks at the long-term safety of the drug zanubrutinib in people with B-cell cancers who were already in a related study. About 955 participants will continue or start taking zanubrutinib. The main goal is to track side effects over time.
Matched conditions: B-CELL MALIGNANCIES
Phase: PHASE3 • Sponsor: BeiGene • Aim: Disease control
Last updated Apr 30, 2026 15:50 UTC